David Gilley, MD
Urology · Greenwood, INNPI 1871750455
Payments from drug & device makers
What this record shows
This record is dominated by other: $22,071 of the $30,905 with a category attached, or 71.4%. Central Indiana URS Consumables, LLC accounts for 71.4% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2024 at $18,034 and has fallen 51.2% since, to $8,795 in 2025. Among urology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $315.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Central Indiana URS Consumables, LLC$22K
- Cook Incorporated$7K
- Astellas Pharma US Inc$145
- Pfizer$140
- Johnson & Johnson$135
- Laborie Medical Technologies Corp.$127
- plus $1K from 31 others
Across 2 payments — averaging $7800.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Central Indiana URS Consumables, LLC$16K
What the payments were for
- Consulting fees$6,91622%
- Travel & lodging$920%
- Food & beverage$1,7916%
- Education$350%
- Other$22,07171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Central Indiana URS Consumables, LLC | 4 | $22,071 |
| Cook Incorporated | 7 | $7,008 |
| Astellas Pharma US Inc | 8 | $145 |
| Pfizer | 7 | $140 |
| Johnson & Johnson | 8 | $135 |
| Laborie Medical Technologies Corp. | 4 | $127 |
| Sanofi | 6 | $121 |
| AstraZeneca | 4 | $97 |
| Bayer | 5 | $95 |
| Dendreon Pharmaceuticals LLC | 3 | $85 |
| Sumitomo Pharma America, Inc. | 3 | $74 |
| Accord Healthcare, Inc. | 3 | $67 |
| Tolmar, Inc. | 3 | $66 |
| Sun Pharmaceutical Industries Inc. | 3 | $62 |
| Procept Biorobotics Corporation | 1 | $59 |
| AbbVie | 3 | $55 |
| Urogen Pharma, Inc. | 2 | $44 |
| Progenics Pharmaceuticals, Inc. | 2 | $40 |
| Endo Pharmaceuticals Inc. | 2 | $37 |
| Calyxo, Inc. | 2 | $32 |
| Novartis | 1 | $30 |
| Hollister Incorporated | 1 | $29 |
| Abbott | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Amgen | 2 | $23 |
| Teleflex LLC | 1 | $21 |
| Coloplast | 1 | $20 |
| Duchesnay USA Incorporated | 1 | $20 |
| Telix Pharmaceuticals | 1 | $20 |
| Medtronic | 1 | $19 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Angiodynamics, Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Bioprotect Medical, Inc. | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dornier MedTech$88,286
- CVAC Aspiration System$22,071
- S~Curve$1,515
How this compares
$30,905 in reported general payments places this provider in the 90th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 149 | $106,091 |
| GemtesaVibegron | 75 | $58,316 |
| Tamsulosin Hcl | 591 | $6,681 |
| Finasteride | 78 | $1,165 |
| Cephalexin | 244 | $1,114 |
| Silodosin | 23 | $1,082 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 17 | $761 |
| NitrofurantoinNitrofurantoin Macrocrystal | 25 | $717 |
| Solifenacin Succinate | 32 | $441 |
| Oxybutynin Chloride | 33 | $318 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 26 | $297 |
| Ciprofloxacin Hcl | 31 | $118 |
| Tramadol Hcl | 79 | $107 |
| Levofloxacin | 42 | $50 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $145 | $106,091149 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $74 | $58,31675 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 272 urology providers in Indiana.
Other urology in Greenwood
- Eugene ConeGreenwood$114K
- Brian OrrGreenwood$50K
- Bradley OrrisGreenwood$29K
- James RaybournGreenwood$27K
- Weston KitleyGreenwood$24K
- Charles SchwabGreenwood$23K
- Alexander TatemCarmel$418K
- Chad ReichardCarmel$400K
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.